SLNO Stock Price | Soleno Therapeutics Inc P/E, Revenue, EPS, & Forecasts

Soleno Therapeutics Inc • SLNO

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Soleno Therapeutics Inc

Ticker

SLNO

Trading on

NASDAQ

ISIN

US8342032005

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Anish Bhatnagar M.D.

Headquarters

100 Marine Parkway, Redwood City, CA, United States, 94065

Employees

Website

https://soleno.life

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Metrics

BasicAdvanced

Market cap

$3.7B

P/E ratio

EPS

-$4.38

Dividend Yield

0.00%

Beta

-2.29

Forward P/E ratio

EBIDTA

$-182M

Ex dividend date

Price & volume

Market cap

$3.7B

Average daily volume

1.6M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

14.92

Earnings

EPS

-$4.38

EPS estimate (current quarter)

$0.00

EPS estimate (next quarter)

$0.00

EBITDA

$-182M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

-2.29

52-week High

$74.50

52-week Low

$36.93

50-day moving average

$56.54

200-day moving average

$51.48

Short ratio

2.11

Short %

11.57%

Management effectiveness

ROE (TTM)

87.35%

ROA (TTM)

45.06%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

49.9M

Float

31.3M

Insiders %

2.41%

Institutions %

103.27%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 8 analysts.

Average price target

$108.63

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.59

-$0.37

59.46%

Q1 • 24Beat

-$0.57

-$0.60

5.00%

Q2 • 24Beat

-$1.83

-$0.63

190.48%

Q3 • 24Beat

-$1.27

-$1.08

17.91%

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-76.6M

∞%

Q3 • 24

$0M

$-56M

∞%

Q4 • 24

NaN%

26.93%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$297M

$32M

10.79%

Q3 • 24

$331M

$85.9M

25.94%

Q4 • 24

11.55%

168.25%

140.48%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-14.9M

$4M

$2.3M

$-15.1M

Q3 • 24

$-24M

$6.4M

$57.1M

$-24M

Q4 • 24

60.73%

59.48%

2,408.26%

58.76%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Soleno Therapeutics Inc share?

Soleno Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Soleno Therapeutics Inc have?

Soleno Therapeutics Inc currently has 49.9M shares.

Does Soleno Therapeutics Inc pay dividends?

No, Soleno Therapeutics Inc doesn't pay dividends.

What is Soleno Therapeutics Inc 52 week high?

Soleno Therapeutics Inc 52 week high is $74.50.

What is Soleno Therapeutics Inc 52 week low?

Soleno Therapeutics Inc 52 week low is $36.93.

What is the 200-day moving average of Soleno Therapeutics Inc?

Soleno Therapeutics Inc 200-day moving average is $51.48.

Who is Soleno Therapeutics Inc CEO?

The CEO of Soleno Therapeutics Inc is Dr. Anish Bhatnagar M.D..

How many employees Soleno Therapeutics Inc has?

Soleno Therapeutics Inc has 92 employees.

What is the market cap of Soleno Therapeutics Inc?

The market cap of Soleno Therapeutics Inc is $3.7B.

What is the P/E of Soleno Therapeutics Inc?

The current P/E of Soleno Therapeutics Inc is null.

What is the EPS of Soleno Therapeutics Inc?

The EPS of Soleno Therapeutics Inc is -$4.38.

What is the PEG Ratio of Soleno Therapeutics Inc?

The PEG Ratio of Soleno Therapeutics Inc is 0.

What do analysts say about Soleno Therapeutics Inc?

According to the analysts Soleno Therapeutics Inc is considered a buy.